Welcome to our dedicated page for Bone Biologics SEC filings (Ticker: BBLG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bone Biologics Corp filings document regulatory disclosures for a clinical-stage orthobiologic developer focused on rhNELL-1 and NB1 in spine fusion markets. Current reports on Form 8-K include Regulation FD updates on corporate, scientific, and operational milestones, along with exhibits tied to public communications.
The company’s filings also cover capital-structure activity, including common stock, warrants, shelf registration statements on Form S-3, prospectus supplements, and at-the-market offering arrangements. These disclosures describe financing tools, securities covered by registration documents, legal opinions, and related material-event reporting.
Bone Biologics Corporation is registering an additional 5,000,000 shares of common stock under its 2015 Equity Incentive Plan. These shares are intended to be issued as equity compensation to employees, directors, and other eligible participants, giving the company more stock available for future grants and awards under the existing plan structure.
The newly registered shares reflect the company’s 1-for-6 reverse stock split effective June 10, 2025 and are being added under streamlined rules that allow registration of extra securities for an already-approved plan. The filing also incorporates the company’s recent annual, quarterly, and current reports by reference and confirms that senior management and directors have authorized the registration.